Clinical Trial Update: Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Velcade (bortezomib) for safety and effectiveness in graft-versus-host disease has completed. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Graft-versus-Host Disease | Phase 2 | Status: COMPLETED | Results posted: 2013-11-28